Tocilizumab in patients with Systemic Juvenile Idiopathic Arthritis (sJIA): 12-week Pharmacokinetic (PK) and Pharmacodynamic (PD) data from the Phase 3 TENDER Trial

被引：0
|
作者：
Ruperto, N. [1 ]
Zhang, A.
Morcos, P. N.
Huppertz, H. [1 ]
Minden, K. [1 ]
Myones, B. [1 ]
Onel, K. [1 ]
Siammopoulou, A. [1 ]
Silva, C. [1 ]
Kenwright, A.
Roseti, S.
De Benedetti, F. [2 ]
Lovell, D. [1 ]
Martini, A. [1 ]
Brunner, H. [1 ]
机构：
[1] IRCCS G Gaslini Pediatria II, Reumatol PRINTO, Genoa, Italy
[2] Bambin Gesu Rome, Rome, Italy
来源：
CLINICAL AND EXPERIMENTAL RHEUMATOLOGY | 2011年 / 29卷 / 02期
关键词：
D O I：
暂无
中图分类号：
R5 [内科学];
学科分类号：
1002 ; 100201 ;
摘要：
引用
收藏
页码：421 / 421
页数：1
相关论文
共 50 条
  • [1] Efficacy and safety of tocilizumab in patients with Systemic Juvenile Idiopathic Arthritis (sJIA): 12-week data from the Phase 3 TENDER trial
    De Benedetti, F.
    Brunner, H.
    Ruperto, N.
    Calvo, I.
    Cutica, R.
    Malattia, C.
    Schneider, R.
    Woo, P.
    Wouters, C.
    Xavier, R.
    Zemel, L.
    Wright, S.
    Kenwright, A.
    Lovell, D.
    Martini, A.
    [J]. CLINICAL AND EXPERIMENTAL RHEUMATOLOGY, 2011, 29 (02) : 371 - 371
  • [2] Tocilizumab improves systemic and laboratory features of Systemic Juvenile Idiopathic Arthritis: 12-week data from the Phase 3 TENDER Trial
    De Benedetti, F.
    Rome, Bambin Gesu
    Ruperto, N.
    Brunner, H.
    Baildam, E.
    Burgos, R.
    Dolezalova, P.
    Garay, S.
    Garcia-Consuegra, J.
    Joos, R.
    Wulffraat, N.
    Zuber, Z.
    Zulian, F.
    Grom, A.
    Schaefer, F.
    Wright, S.
    Kenwright, A.
    Martini, A.
    Lovell, D.
    [J]. CLINICAL AND EXPERIMENTAL RHEUMATOLOGY, 2011, 29 (02) : 415 - 415
  • [3] Tocilizumab Is efficacious in patients with Systemic Juvenile Idiopathic Arthritis (sJIA) across baseline disease characteristics and prior/baseline treatments: 12-week data from the Phase 3 TENDER Trial
    Ruperto, N.
    De Benedetti, F.
    Brunner, H.
    Allen, R.
    Brown, D.
    Chaitow, J.
    Cortis, E.
    Espada, G.
    Flato, B.
    Gerloni, V.
    Horneff, G.
    Wright, S.
    Kenwright, A.
    Schneider, R.
    Woo, P.
    Martini, A.
    Lovell, D.
    [J]. CLINICAL AND EXPERIMENTAL RHEUMATOLOGY, 2011, 29 (02) : 370 - 371
  • [4] TOCILIZUMAB IN PATIENTS WITH SYSTEMIC JUVENILE IDIOPATHIC ARTHRITIS: EFFICACY DATA FROM THE PLACEBO-CONTROLLED 12-WEEK PART OF THE PHASE III TENDER TRIAL
    Chaitow, J.
    De Benedetti, F.
    Brunner, H.
    Ruperto, N.
    Allen, R.
    Murray, K.
    Schneider, R.
    Woo, P.
    Wright, S.
    Kenwright, A.
    Martini, A.
    Lovell, D.
    [J]. INTERNAL MEDICINE JOURNAL, 2011, 41 : 32 - 32
  • [5] Efficacy and safety of tocilizumab (TCZ) in patients with systemic juvenile idiopathic arthritis (SJIA): tender 52-week data
    F De Benedetti
    H Brunner
    N Ruperto
    R Schneider
    P Woo
    R Burgos-Vargas
    P Dolezalova
    R Joos
    N Wulffraat
    Z Zuber
    F Zulian
    R Allen
    D Brown
    J Chaitow
    M Pardeo
    G Espada
    B Flato
    V Gerloni
    G Horneff
    S Wright
    A Kenwright
    D Lovell
    A Martini
    [J]. Pediatric Rheumatology, 9 (Suppl 1)
  • [6] Efficacy and safety of tocilizumab (TCZ) in patients with systemic juvenile idiopathic arthritis (sJIA): TENDER 52-week data
    Fabrizio De Benedetti
    Hermine Brunner
    Nicola Ruperto
    R Cuttica
    Clara Malattia
    Rayfel Schneider
    Patricia Woo
    Despina Eleftheriou
    Eileen Baildam
    Ruben Burgos-Vargas
    Pavla Dolezalova
    Stella M Garay
    Rik Joos
    Nico Wulffraat
    Zbyszek Zuber
    Francesco Zulian
    Carine Wouters
    Ricardo M Xavier
    Lawrence Zemel
    Stephen Wright
    Andy Kenwright
    Alberto Martini
    Daniel Lovell
    [J]. Pediatric Rheumatology, 10 (Suppl 1)
  • [7] PHARMACOKINETICS (PK) AND PHARMACODYNAMICS (PD) OF TOCILIZUMAB (TCZ) IN SYSTEMIC JUVENILE IDIOPATHIC ARTHRITIS (sJIA).
    Zhang, X.
    Morcos, P. N.
    De Benedetti, F.
    Brunner, H.
    Ruperto, N.
    Schaefer, F.
    Roseti, S.
    Kenwright, A.
    Martini, A.
    Lovell, D.
    [J]. CLINICAL PHARMACOLOGY & THERAPEUTICS, 2011, 89 : S36 - S36
  • [8] EFFICACY AND SAFETY OF TOCILIZUMAB (TCZ) IN PATIENTS WITH SYSTEMIC JUVENILE IDIOPATHIC ARTHRITIS (SJIA): 2-YEAR DATA FROM TENDER, A PHASE 3 CLINICAL TRIAL
    De Benedetti, F.
    Brunner, H.
    Ruperto, N.
    Kenwright, A.
    Devlin, C.
    Calvo, I.
    Cuttica, R.
    Ravelli, A.
    Schneider, R.
    Eleftheriou, D.
    Wouters, C.
    Xavier, R.
    Zemel, L.
    Baildam, E.
    Burgos-Vargas, R.
    Dolezalova, P.
    Garay, S. M.
    Joos, R.
    Grom, A.
    Wulffraat, N.
    Zuber, Z.
    Zulian, F.
    Lovell, D.
    Martini, A.
    [J]. ANNALS OF THE RHEUMATIC DISEASES, 2013, 71 : 425 - 425
  • [9] THE EFFICACY OF TOCILIZUMAB IN PATIENTS WITH SYSTEMIC JUVENILE IDIOPATHIC ARTHRITIS: 52-WEEK DATA FROM A PHASE 3 CLINICAL TRIAL
    De Benedetti, Fabrizio
    Brunner, Hermine
    Allen, Roger
    Brown, Diane
    Chaitow, Jeffrey
    Pardeo, Manuela
    Espada, Graciela
    Flato, Berit
    Horneff, Gerd
    Devlin, Clare
    Kenwright, Andrew
    Schneider, Rayfel
    Woo, Patricia
    Martini, Alberto
    Lovell, Daniel
    Ruperto, Nicola
    [J]. RHEUMATOLOGY, 2012, 51 : 76 - 76
  • [10] Efficacy of Canakinumab in Patients with Systemic Juvenile Idiopathic Arthritis (SJIA) using JADAS Criteria - an Analysis of 12-Week Pooled Data
    Ravelli, A.
    Brunner, H. I.
    Ruperto, N.
    Quartier, P.
    Consolaro, A.
    Wulffraat, N. M.
    Lheritier, K.
    Gaillez, C.
    Martini, A.
    Lovell, D. J.
    [J]. ARTHRITIS & RHEUMATOLOGY, 2014, 66 : S1002 - S1003
12345